Urologix to Host Its Fiscal Year 2013 Second Quarter Conference Call

  Urologix to Host Its Fiscal Year 2013 Second Quarter Conference Call

Business Wire

MINNEAPOLIS -- January 30, 2013

Urologix^®, Inc. (Nasdaq:ULGX) will host a conference call to present fiscal
year 2013 second quarter results on Tuesday, February 5, 2013 at 4:00 p.m. CT,
following the Company’s post-market press release on the same day. On the day
of the call, please dial 1-866-578-5788 and enter the Participant Passcode
18011408 at least 10 minutes prior to the call. The conference call will be
broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief
Executive Officer, will host the call.

Webcast listeners should log on at least 10 minutes prior to the scheduled
start time of the call to register and download or install any required audio
software. A replay of the call will be available until February 12, 2013 at
4:00 p.m. CT (5:00 p.m. ET). To listen to the replay, please dial
1-888-286-8010 and enter the Participant Passcode 54233981.

The webcast is also being distributed over CCBN’s Investor Distribution
Network to both institutional and individual investors. Individual investors
can listen to the call through CCBN’s individual investor center at
www.companyboardroom.com or by visiting any of the investor sites in CCBN’s
Individual Investor Network. Institutional investors can access the call via
CCBN’s password-protected event management site, StreetEvents

About Urologix

Urologix, Inc., based in Minneapolis, develops, manufactures, markets and
distributes minimally invasive medical products for the treatment of
obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’
Cooled ThermoTherapy™ produces targeted microwave energy combined with a
unique cooling mechanism to protect healthy tissue and enhance patient
comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and
Targis® Control Units and the CTC Advance® and Targis® catheter families. The
Prostiva® RF Therapy System distributed by Urologix delivers radio frequency
energy directly into the prostate destroying prostate tissue, reducing
constriction of the urethra, and thereby relieving BPH voiding symptoms. Both
of these products provide safe, effective and lasting relief of the symptoms
and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic,
Inc., used under license. All other trademarks are the property of Urologix.


Urologix, Inc.
Brian Smrdel, Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.